New CEO views U.S. as critical turfThe integration at Philips Medical Solutions is done. Research and design and marketing and sales have closed ranks, joining best-of-breed technologies into a cohesive blend of offerings,
New CEO views U.S. as critical turf
The integration at Philips Medical Solutions is done. Research and design and marketing and sales have closed ranks, joining best-of-breed technologies into a cohesive blend of offerings, according to the company's chief executive, Jouko Karvinen. The glue that keeps it all together is a sincere and deep passion for clinical applications.
"We try to understand the good that comes from our products," he said. "What good they do for doctors and, more important, for patients."
Karvinen has been at the helm of Philips Medical for just over half a year, replacing Hans Barella as president and CEO on Oct. 1, 2002. Partnering with customers is the key to his strategy today, just as it was when he ran the automation technology products division of ABB Group in Zurich, Switzerland, before joining Philips.
Only by understanding the needs of customers can a company meet them, he said. And Philips competitors tend not to do this.
"I was speaking to one person at a university and he told me, 'Everybody is saying they have solutions for me, but nobody is asking me about my problems,'" Karvinen said. "I think there is a lot of truth there."
While serving as executive vice president of the ABB Group, Karvinen was under intense pressure to meet customer needs. The average life cycle of automation equipment is 18 months. By comparison, meeting the needs of customers accustomed to a five to seven-year equipment life cycle should be a breeze. But Karvinen doesn't see it that way. He is on the road 80% of his time, talking to physicians, pitching deals to administrators, mingling at trade shows.
He refers to Philips' staff as "troops," the fight for market share as a "war." To Karvinen, the U.S. is critical turf.
"We cannot win the world without this country," he said. "We have to win here, because the U.S. is the leading market in the world. That is one of the reasons we put world headquarters in the U.S. The other is that half of my researchers are here."
Establishing partnerships with luminaries is essential in the race to develop new and better Philips technology, he said. But developing the best MR or CT, x-ray, nuc med, or ultrasound system will get the company only so far.
"We are not going to win this war based on modality technologies," he said. "You can take a step ahead of the competition and gain an edge, but you will not take over the world with it."
Applications areas, such as women's health, are drawing in multiple modalities. In two or maybe three years, modality technologies will be the entry requirement to compete for sales based on applications, according to Karvinen. For Philips to succeed, technology must be translated into clinical applications and, ultimately, into workflow improvements.
Winning sales in the future, as now, will depend on forging strong relationships with customers. Physicians will be the backbone of those relationships. But nonmedical decision-makers must also be involved. And Philips will reach out to the patient as well, as part of a multilayer relationship with the imaging community, he said.
"More and more in the future patients will have a say in how they are medically treated," he said. "In the U.S. they have a lot to say now, and in the future, they will have even more."
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
2 Commerce Drive
Cranbury, NJ 08512